[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing Shihejiyin Technology, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100516988","the-jinling-cohort-100516988",false,"NCT06011694","The Jinling Cohort","A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population","Inclusion Criteria:\n\n1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent\n\nExclusion Criteria:\n\n1. Pregnant women;\n2. Individuals who have history of cancer or current diagnosis of cancer;\n3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n4. Individulas who have blood transfusion within 30 days prior to the blood draw;\n5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw;\n6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw;\n7. Individuals who will not be able to comply with the protocol procedures judged by researchers",true,"ALL","45 Years","75 Years",{"count":21,"type":22},15000,"ESTIMATED","OBSERVATIONAL","The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.",[26,27,28],"Cancer","Multi Cancer Early Screening","Liquid Biopsy",[30,31],"Early Detection of Cancer","MCED","RECRUITING","2023-08-23",{"date":35,"type":36},"2023-08-25","ACTUAL",{"date":38,"type":36},"2022-06-15",{"date":40,"type":22},"2027-05-15",{"name":42,"class":43},"Nanjing Shihejiyin Technology, Inc.","INDUSTRY",2,""]